ESMO 2021

Immune Response Dynamics in Patients with Cancer Following COVID-19 Vaccination

The anti-S antibody response after the first vaccine dose was greatly enhanced in individuals who had recovered from prior SARS-CoV-2 infection compared with those who were SARS-CoV-2 naive.

Orelabrutinib and MIL62 Combination Therapy Well Tolerated for Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.

Tumor Microenvironment Cellular Makeup May Predict Nivolumab Response for Patients With Hodgkin Lymphoma

Researchers sought to determine whether tumor microenvironment levels of M2 macrophages could predict response to nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Thromboprophylaxis Is Safe and Effective in Patients With High-Risk Cancer

Intermediate anticoagulation doses appear to be safe and effective as thromboprophylaxis in patients with high thrombotic risk active cancer.

Effectiveness of Corticosteroids in the Treatment of Chemotherapy-Induced Thrombocytopenia

Researchers sought to determine whether corticosteroids would be an effective treatment for patients with chemotherapy-induced thrombocytopenia.

Superior Efficacy With Copanlisib Plus Rituximab vs Placebo Plus Rituximab in Patients With Relapsed Marginal Zone Lymphoma

Patients were randomly assigned 2:1 to copanlisib plus rituximab or placebo plus rituximab.

Tipifarnib May Yield Response in Chronic Myelomonocytic Leukemia or Other Myelodysplastic, Myeloproliferative Neoplasms

Among patients with CML, 32 were evaluable for ORR, which was determined to be 21.9%.

ONKOTEV Scoring System May Be Predictive of VTE Risk Among Outpatients With Cancer

The cumulative 12-month incidence of venous thromboembolism was 12.7%.

Technology-Based Psychosocial Program Effective for Adolescent Leukemia Survivors

The program includes 10 weeks of education and counseling with 5 modules and 3 months’ of follow-up.

R-NPLD Combination Treatment Safe and Effective for Patients With Diffuse Large B-Cell Lymphoma

Researchers sought to determine whether R-NPLD would be an effective therapy in older patients with DLBCL.

APN Follow-Up Intervention Improves Care for Patients With Multiple Myeloma

Researchers sought to determine whether a follow-up protocol involving APN management would be beneficial for patients with multiple myeloma treated with oral chemotherapy.

Interleukin-6 Levels May Predict PFS in Relapsed/Refractory Hodgkin Lymphoma Treated With Nivolumab

Researchers sought to determine whether interleukin-6 levels would be predictive of survival in patients with Hodgkin lymphoma receiving nivolumab.

Patients With Cancer and COVID-19 Face Increased Risk of Thromboembolic Events

Researchers sought to determine whether patients with cancer who had COVID-19 had an increased risk of experiencing thromboembolic events.

Long-Term Follow-Up Care: Needs and Expectations of Adolescent Survivors of Childhood Leukemia

Adolescent survivors of childhood leukemia reported that they expect follow-up care to address support needs mostly in terms of psychosocial and emotional aspects.

High Rates of COVID-19 Mortality Seen in Patients With Hematological Malignancies

At data cutoff, 562 of 626 patients enrolled in the study were eligible for primary endpoint assessment.

Botanical-Derived Drug May Be Clinically Active in Multiple Cancer Types

A novel anticancer drug derived from botanical molecules, appears to show clinical activity across a wide range of malignancies.

Hyperamylasemia Linked With Inferior Survival in Patients With Multiple Myeloma

Researchers sought to determine whether higher amylase levels would be linked with more advanced disease as well as inferior survival in patients with multiple myeloma.